Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 11/2018

01-11-2018 | Pictorial essay

Pancreatic neuroendocrine tumor: review of heterogeneous spectrum of CT appearance

Authors: Nam Ju Lee, Ralph H. Hruban, Elliot K. Fishman

Published in: Abdominal Radiology | Issue 11/2018

Login to get access

Abstract

Objective

Pancreatic neuroendocrine tumors (PanNETs) are uncommon pancreatic neoplasms and can be a diagnostic challenge with heterogeneous spectrum of CT appearance. We review CT findings of PanNETs and other mimics.

Conclusion

PanNETs are typically hypervascular and have avid enhancement on arterial and venous phase images. However, dedicated pancreas protocol may be needed due to their sometimes atypical appearance including transient enhancement. Careful evaluation of CT findings will help differentiate PanNETs from their mimics, and can be used to establish the diagnosis of a PanNETs. Although an accurate diagnosis can be based on serological, urine, and CT scan findings, confirmation is made via pathological examination.
Literature
1.
Rindi G, Wiedenmann B (2011) Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol 8(1):54–64CrossRef
2.
Lloyd RV OR, Klöppel G, Rosai J (ed) (2017) WHO/IARC Classification of Tumours, vol 10. WHO Classification of Tumours of Endocrine Organs, 4th edn,
3.
Scoazec JY, Couvelard A (2017) Classification of pancreatic neuroendocrine tumours: changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future. Ann Pathol 37(6):444–456CrossRef
4.
Kloppel G (2017) Neuroendocrine neoplasms: dichotomy, origin and classifications. Visc Med 33(5):324–330CrossRef
5.
Han X, Xu X, Ma H, et al. (2018) Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology. Endocr Connect 7(2):355–363CrossRef
6.
Tang LH, Untch BR, Reidy DL, et al. (2016) Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res 22(4):1011–1017CrossRef
7.
Sorbye H, Welin S, Langer SW, et al. (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 24(1):152–160CrossRef
8.
Modlin IM, Oberg K, Chung DC, et al. (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9(1):61–72CrossRef
9.
Zerbi A, Falconi M, Rindi G, et al. (2010) Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol 105(6):1421–1429CrossRef
10.
Wiedenmann B, Waldherr R, Buhr H, et al. (1988) Identification of gastroenteropancreatic neuroendocrine cells in normal and neoplastic human tissue with antibodies against synaptophysin, chromogranin A, secretogranin I (chromogranin B), and secretogranin II. Gastroenterology 95(5):1364–1374CrossRef
11.
Kawamoto S, Johnson PT, Shi C, et al. (2013) Pancreatic neuroendocrine tumor with cystlike changes: evaluation with MDCT. Am J Roentgenol 200(3):W283–W290CrossRef
12.
Metz DC, Jensen RT (2008) Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135(5):1469–1492CrossRef
13.
14.
Kawamoto S, Shi C, Hruban RH, et al. (2011) Small serotonin-producing neuroendocrine tumor of the pancreas associated with pancreatic duct obstruction. Am J Roentgenol 197(3):W482–W488CrossRef
15.
Kloppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 18(Suppl 1):S1–S16CrossRef
16.
Anlauf M, Garbrecht N, Bauersfeld J, et al. (2007) Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch 451(Suppl 1):S29–S38CrossRef
17.
Lubensky IA, Pack S, Ault D, et al. (1998) Multiple neuroendocrine tumors of the pancreas in von Hippel–Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 153(1):223–231CrossRef
18.
Grant CS (2005) Insulinoma. Best Pract Res Clin Gastroenterol 19(5):783–798CrossRef
19.
Bilimoria KY, Tomlinson JS, Merkow RP, et al. (2007) Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg 11(11):1460–1467; discussion 1467–1469CrossRef
20.
Jani N, Khalid A, Kaushik N, et al. (2008) EUS-guided FNA diagnosis of pancreatic endocrine tumors: new trends identified. Gastrointest Endosc 67(1):44–50CrossRef
21.
Schmitt AM, Anlauf M, Rousson V, et al. (2007) WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 31(11):1677–1682CrossRef
22.
Kapran Y, Bauersfeld J, Anlauf M, Sipos B, Kloppel G (2006) Multihormonality and entrapment of islets in pancreatic endocrine tumors. Virchows Arch 448(4):394–398CrossRef
23.
Zavras N, Schizas D, Machairas N, et al. (2017) Carcinoid syndrome from a carcinoid tumor of the pancreas without liver metastases: a case report and literature review. Oncol Lett 13(4):2373–2376CrossRef
24.
Ramage JK, Ahmed A, Ardill J, et al. (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61(1):6–32CrossRef
25.
Lewis RB, Lattin GE Jr, Paal E (2010) Pancreatic endocrine tumors: radiologic–clinicopathologic correlation. Radiographics 30(6):1445–1464CrossRef
26.
Ichikawa T, Peterson MS, Federle MP, et al. (2000) Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 216(1):163–171CrossRef
27.
King AD, Ko GT, Yeung VT, et al. (1998) Dual phase spiral CT in the detection of small insulinomas of the pancreas. Br J Radiol 71(841):20–23CrossRef
28.
Stafford Johnson DB, Francis IR, Eckhauser FE, Knol JA, Chang AE (1998) Dual-phase helical CT of nonfunctioning islet cell tumors. J Comput Assist Tomogr 22(1):59–63CrossRef
29.
Rockall AG, Reznek RH (2007) Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 21(1):43–68CrossRef
30.
Debray MP, Geoffroy O, Laissy JP, et al. (2001) Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol 74(887):1065–1070CrossRef
31.
Patel KK, Kim MK (2008) Neuroendocrine tumors of the pancreas: endoscopic diagnosis. Curr Opin Gastroenterol 24(5):638–642CrossRef
32.
Ahrendt SA, Komorowski RA, Demeure MJ, Wilson SD, Pitt HA (2002) Cystic pancreatic neuroendocrine tumors: is preoperative diagnosis possible? J Gastrointest Surg 6(1):66–74CrossRef
33.
Bordeianou L, Vagefi PA, Sahani D, et al. (2008) Cystic pancreatic endocrine neoplasms: a distinct tumor type? J Am Coll Surg 206(6):1154–1158CrossRef
34.
Baker MS, Knuth JL, DeWitt J, et al. (2008) Pancreatic cystic neuroendocrine tumors: preoperative diagnosis with endoscopic ultrasound and fine-needle immunocytology. J Gastrointest Surg 12(3):450–456CrossRef
35.
Figueiredo FA, Giovannini M, Monges G, et al. (2009) EUS-FNA predicts 5-year survival in pancreatic endocrine tumors. Gastrointest Endosc 70(5):907–914CrossRef
36.
Atiq M, Bhutani MS, Bektas M, et al. (2012) EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience. Dig Dis Sci 57(3):791–800CrossRef
37.
Adsay NV (2008) Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg 12(3):401–404CrossRef
38.
Adsay NV, Klimstra DS (2000) Cystic forms of typically solid pancreatic tumors. Semin Diagn Pathol 17(1):81–88PubMed
39.
Ligneau B, Lombard-Bohas C, Partensky C, et al. (2001) Cystic endocrine tumors of the pancreas: clinical, radiologic, and histopathologic features in 13 cases. Am J Surg Pathol 25(6):752–760CrossRef
40.
Park HS, Kim SY, Hong SM, et al. (2016) Hypervascular solid-appearing serous cystic neoplasms of the pancreas: differential diagnosis with neuroendocrine tumours. Eur Radiol 26(5):1348–1358CrossRef
41.
Raman SP, Hruban RH, Cameron JL, Wolfgang CL, Fishman EK (2012) Pancreatic imaging mimics: part 2, pancreatic neuroendocrine tumors and their mimics. Am J Roentgenol 199(2):309–318CrossRef
42.
Lee NJ, Hruban RH, Fishman EK (2017) Abdominal schwannomas: review of imaging findings and pathology. Abdom Radiol (NY) 42(7):1864–1870CrossRef
43.
Adsay NV, Klimstra DS, Compton CC (2000) Cystic lesions of the pancreas. Introduction. Semin Diagn Pathol 17(1):1–6PubMed
44.
Klimstra DS, Wenig BM, Heffess CS (2000) Solid-pseudopapillary tumor of the pancreas: a typically cystic carcinoma of low malignant potential. Semin Diagn Pathol 17(1):66–80PubMed
45.
Lee JH, Byun JH, Kim JH, et al. (2014) Solid pancreatic tumors with unilocular cyst-like appearance on CT: differentiation from unilocular cystic tumors using CT. Korean J Radiol 15(6):704–711CrossRef
46.
Singhal D, Kakodkar R, Sud R, Chaudhary A (2006) Issues in management of pancreatic pseudocysts. JOP 7(5):502–507PubMed
47.
Gallotti A, Johnston RP, Bonaffini PA, et al. (2013) Incidental neuroendocrine tumors of the pancreas: MDCT findings and features of malignancy. Am J Roentgenol 200(2):355–362CrossRef
48.
Horton KM, Hruban RH, Yeo C, Fishman EK (2006) Multi-detector row CT of pancreatic islet cell tumors. Radiographics 26(2):453–464CrossRef
49.
Rha SE, Jung SE, Lee KH, et al. (2007) CT and MR imaging findings of endocrine tumor of the pancreas according to WHO classification. Eur J Radiol 62(3):371–377CrossRef
50.
Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ (2005) Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomark Prev 14(7):1766–1773CrossRef
51.
Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM (2008) Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer 15(2):409–427CrossRef
52.
Scarpa A, Mantovani W, Capelli P, et al. (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23(6):824–833CrossRef
53.
Mogoanta SS, Costache A, Mutiu G, et al. (2015) A nonfunctional neuroendocrine tumor of the pancreas—a case report. Rom J Morphol Embryol 56(2):511–519PubMed
54.
Takaji R, Matsumoto S, Mori H, et al. (2009) Carcinoid tumors of the pancreas: dynamic CT and MRI features with pathological correlation. Abdom Imaging 34(6):753–758CrossRef
55.
Buetow PC, Parrino TV, Buck JL, et al. (1995) Islet cell tumors of the pancreas: pathologic-imaging correlation among size, necrosis and cysts, calcification, malignant behavior, and functional status. Am J Roentgenol 165(5):1175–1179CrossRef
56.
He XW, Wu XJ, He XS, et al. (2009) Clinicopathologic analysis of eight cases of pancreatic carcinoid tumors. Chin Med J (Engl) 122(13):1591–1594
57.
Liu FH, Wang C, Xing YL, Wu JH, Tang Y (2015) Clinical characteristics and prognosis of primary pancreatic carcinoid tumors: a report of 13 cases from a single institution. Oncol Lett 9(2):780–784CrossRef
58.
Yao KA, Talamonti MS, Nemcek A, et al. (2001) Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130(4):677–682; discussion 682–675CrossRef
59.
Brentjens R, Saltz L (2001) Islet cell tumors of the pancreas: the medical oncologist’s perspective. Surg Clin N Am 81(3):527–542CrossRef
60.
Sarmiento JM, Que FG (2003) Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 12(1):231–242CrossRef
61.
Rothman H, Cantrell JE Jr, Lokich J, et al. (1991) Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program study. Cancer 68(2):264–268CrossRef
62.
Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin–doxorubicin, streptozocin–fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326(8):519–523CrossRef
63.
Woltering EA, Mamikunian PM, Zietz S, et al. (2005) Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas 31(4):392–400CrossRef
64.
Schran HF, Hager DF (2008) Comments on “Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients”. Pancreas 37(3):334–335; author reply 336–337CrossRef
65.
Hofman MS, Lau WF, Hicks RJ (2015) Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 35(2):500–516CrossRef
Metadata
Title
Pancreatic neuroendocrine tumor: review of heterogeneous spectrum of CT appearance
Authors
Nam Ju Lee
Ralph H. Hruban
Elliot K. Fishman
Publication date
01-11-2018
Publisher
Springer US
Published in
Abdominal Radiology / Issue 11/2018
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-018-1574-4

Other articles of this Issue 11/2018

Abdominal Radiology 11/2018 Go to the issue

OriginalPaper

Defining the abdominal radiologist based on the current U.S. job market

OriginalPaper

New intra-abdominal mass after operation for colorectal cancer: desmoid tumor versus peritoneal seeding

Classics in Abdominal Radiology

String sign of Kantor

Pictorial essay

Small bowel obstruction and the gastrografin challenge

OriginalPaper

Dual-layer spectral detector CT: non-inferiority assessment compared to dual-source dual-energy CT in discriminating uric acid from non-uric acid renal stones ex vivo

OriginalPaper

Three-dimensional CT enterography versus barium follow-through examination in measurement of remnant small intestinal length in short bowel syndrome patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits